Moderna Surges 177% to 3-Year High on Positive Cancer Vaccine Test Results
Updated
Updated · Investor's Business Daily · Aug 21
Moderna Surges 177% to 3-Year High on Positive Cancer Vaccine Test Results
3 articles · Updated · Investor's Business Daily · Aug 21
Summary
Moderna shares jumped 177% on Wednesday, sending the stock to a three-year high after the company reported positive results for a cancer vaccine targeting certain tumor types.
The test data showed patients went longer before relapse, giving investors fresh evidence that Moderna’s mRNA platform may have commercial potential beyond its COVID business.
That rally builds on this week’s late-stage melanoma trial success for Intismeran with Merck’s Keytruda, where the Phase 3 INTerpath-001 study enrolled 1,137 patients.
The surge also fed a broader market narrative that AI-driven investor money could rotate away from memory and data-center names toward companies applying generative AI in drug development.